
        <!DOCTYPE html>
    <html lang="ja">
    <style>
    body
    {
        color: black;
        background-color: white;
    }
    div{
        font-size: 14px;
    }
    span
    {
        font-size: 18px;
    }
    #grad1{
        background: linear-gradient(transparent 60%,#99e4f1 30%);
        font-size: 18px;
        font-weight: bold;
    }
    #grad2{
        background: linear-gradient(transparent 60%,#fda1a1 30%);
        font-size: 18px;
        font-weight: bold;
    }

    </style>

    <head>
        <meta charset="UTF-8">
        <title>105-268</title>
    </head>

    <body>
        <h1>
        <a href="./105_267.html" rel="external" title="prev">≪</a>
        105-268
        <a href="./105_269.html" rel="external" title="next">≫</a>
        </h1>
        <div class='problem'>
            <p>
                <span id="grad1">　問題文　</span>
            </p>
            <p>
                <p>65歳男性。花粉症のため近医を受診した。医師が服用中の薬について確認したところ、以下の処方による治療を受けていることがわかった。そこで、医師は地域連携の会議等でよく顔を合わせている薬剤師に電話して、抗アレルギー剤の選択について相談した。</p>
<p><img alt="" class="alignnone size-full wp-image-21174" height="122.49999999999999" loading="lazy" sizes="(max-width: 692px) 100vw, 692px" src="data:;base64,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" width="484.4"/></p>
<h4>問268</h4>
<p>以下の抗アレルギー剤のうち、処方を避けることが望ましい薬剤として、医師に伝えるのはどれか。1つ選べ。</p>
<ol><li>アゼラスチン塩酸塩錠</li><li>エバスチン錠</li><li>ケトチフェンフマル酸塩錠</li><li>ジフェンヒドラミン塩酸塩錠</li><li>レボセチリジン塩酸塩錠</li></ol>
<h4>問269</h4>
<p>その薬剤の処方を避けることが望ましい理由として、適切なのはどれか。1つ選べ。</p>
<ol><li>テルミサルタンの血漿タンパク結合を阻害するため。</li><li>テルミサルタンの代謝を阻害するため。</li><li>沈降炭酸カルシウムへの吸着により、その薬物の薬効が減弱するため。</li><li>肝機能障害患者では、その薬物の活性代謝物への代謝が抑制されるため。</li><li>腎機能障害患者では、その薬物の高い血中濃度が持続するため。</li></ol>    
            </p>
        </div>
        <hr>

        <input type="button" value="check ans" onclick="toggle_switch()"/>
        
        <div id='toggle'>
        <div class='answer'>
            <p>
                <span id="grad2">　解答　　</span>
            </p>
            <p>
            問268：5問269：5
            </p>
        </div>
        <div class='description'>
            <p>
                <span id="grad2">　解説　　</span>
            </p>
            <h4>問268</h4>
<p>問 269 と合わせて解説します。</p>
<h4>問269</h4>
<p>処方に沈降炭酸カルシウム錠があるため、腎不全がかなり進行しています。</p>
<p>問 268 の選択肢の中で<br/>レボセチリジン（ザイザル）は、クレアチニンクリアランスに応じて投与量の調節が必要です。そして、重度の腎障害患者への投与は禁忌です。代替薬もあることをふまえると、レボセチリジンを避けることが望ましいと考えられます。</p>
<p>以上より<br/>問 268 の正解は 5 です。<br/>問 269 の正解は 5 です。</p>
            </p>
        </div>
        </div>
    </body>
    <script>
    document.getElementById("toggle").style.display="none";
    function toggle_switch(){
        var x = document.getElementById("toggle");
        if (x.style.display=="block"){
            x.style.display="none";
        }
        else{
            x.style.display="block";
        }
    }
    </script>
    